Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: A novel therapeutic management for diabetes patients with chronic limb-threatening ischemia: comparison of autologous bone marrow mononuclear cells versus allogenic Wharton jelly-derived mesenchymal stem cells

Fig. 6

Diabetic patients with CTLI showed drastically reduced pain-free walking after auto-BM-MNC or allo-WJ-MSC treatment. Pain-free walking distance diminished from the first month of treatment with auto-BM-MNC and allo-WJ-MSCs, unlike in the placebo group. Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (p < 0.05); placebo group versus allo-WJ-MSC group (*) (p < 0.05); auto-BM-MNC group versus allo-WJ-MSC group (%) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group one month post-treatment (ϖ) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group three months post-treatment (ϕ) (p < 0.05); allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group six months post-treatment (φ) (p < 0.05) and allo-WJ-MSC group pre-treatment versus allo-WJ-MSC group twelve months post-treatment (Ω) (p < 0.05). Auto-BM-MNC, autologous bone marrow mononuclear cell and allo-WJ-MSCs, allogenic Wharton jelly-derived mesenchymal stem cells

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512